Tacrolimus

Transplant therapeutic drug monitoring assays, such as Sirolimus and Tacrolimus, as well as Cyclosporine, are used as an aid in the management of allograft recipients receiving immunosuppressive drug (ISD) therapy.

Therapeutic drug monitoring (TDM) of transplant patients provides unique challenges to the laboratory due to the various immunosuppressive drug combinations that are prescribed. For the treatment to be optimal, clinicians need an accurate determination of a patient’s immunosuppressive drug concentration in whole blood.

 

Challenges

 

 

Organ transplant waiting list

The number of solid organ transplant procedures performed is limited by organ availability. The waiting list grows every year.

 
hands_338x170.jpg
 

Every ten minutes, someone is added to the national transplant waiting list.

On average, 22 people die each day while waiting for a transplant. 1
1 https://optn.transplant.hrsa.gov/ accessed January 23, 2017

Low Dose Therapies

The best patient outcomes seem to be achieved by maintaining the right balance of a combination of ISDs (cocktail therapy) at lower dosage levels to reduce toxicity and prevent graft loss. 

lowdose_tacrolimus.jpg

Accurate and precise measurement of tacrolimus concentration, followed by optimal tacrolimus dosing, could improve patient quality of life and ensure long term survival of both the patient and allograft by reducing drug toxicity while maintaining adequate immunosuppression during low dose therapy.

 Current Challenges for The Laboratory

sensitivity_338x170.jpg

Sensitivity and accuracy

interference_338x170.jpg

interference

 

consistency_338x170.jpg

consistency

 

The Value of Architect Tacrolimus2

 

The automated ARCHITECT Tacrolimus Assay offers the ease of use laboratories need, the turnaround time clinicians require, all with the low-end assay sensitivity and performance required for post-transplant patient therapeutic drug monitoring.

Excellent Sensitivity:
Better Detection

  • First Immunoassay that meets European Consensus recommendation of 1 ng/mL or lower for LOQ
Improved Accuracy and Precision:
Better Reliability

  • The ARCHITECT assay is both accurate and precise at low concentrations of tacrolimus between labs
Minimal Interference:
Better Predictability
  • Pre-treatment removes interfering substances
Lab-To-Lab Consistency: 
Better Comparability
  • Correlates well with LC-MS/MS methods and provides consistent and timely results across labs worldwide
ARCHITECT Tacrolimus Package Insert 607-018 7/15/ R10 September 2015
With Abbott architect, you should be capable of implementing a best in class tacrolimus assay with a total %cv of 6-8% at low trough concentrations
(3-5NG/ML).

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No